Physician profile
Mayar Jundi
NPI 1962601435
$7,974.62
in general payments reported to CMS, 2019-2025
45 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,886 · 2020: $588 · 2021: $332 · 2022: $991 · 2023: $2,470 · 2024: $640 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,039 · Travel and Lodging: $1,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.12 |
| Travel and Lodging | $1,138.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,559.87 | 2023 | Pascal |
| Abbott Laboratories | $1,243.37 | 2019-2025 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $763.16 | 2019-2025 | |
| Pfizer INC. | $397.17 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $393.72 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $320.15 | 2019-2025 | Camzyos, Eliquis |
| Kestra Medical Technology Services, INC. | $279.32 | 2023-2025 | Assure Wcd |
| Amgen INC. | $269.02 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $261.31 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.89 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $183.68 | 2019-2023 | |
| Abiomed | $163.18 | 2023-2025 | Impella |
| Astellas Pharma US INC | $142.42 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $126.03 | 2019-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $121.22 | 2022-2024 | Verquvo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $116.96 | 2019-2020 | |
| Novo Nordisk INC | $107.52 | 2024 | Wegovy |
| Philips North America LLC | $103.16 | 2020-2024 | (5044) Mcot, (Cm9) Amb Mon & Diag Und |
| United Therapeutics Corporation | $98.03 | 2023-2025 | Tyvaso, Remodulin, Tyvaso |
| Medtronic, INC. | $96.32 | 2021-2025 | Symplicity G3, Linq II |
| Astrazeneca Pharmaceuticals LP | $96.08 | 2019-2024 | Farxiga |
| Atricure, INC. | $87.34 | 2022-2024 | |
| Boston Scientific Corporation | $86.18 | 2019-2022 | |
| Scpharmaceuticals INC. | $83.70 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $71.73 | 2022 | |
| Ge Healthcare | $64.26 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.89 | 2021-2025 | |
| Siemens Medical Solutions USA, INC. | $54.05 | 2024-2025 | Biograph Trinion Ep Ct64, Acuson Origin Diagnostic Ultrasound System, Sensis |
| Irhythm Technologies, INC. | $49.43 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Kowa Pharmaceuticals America, INC. | $47.43 | 2020 | |
| Portola Pharmaceuticals, LLC | $44.37 | 2019 | |
| Arbor Pharmaceuticals, INC. | $39.65 | 2019-2020 | |
| Amarin Pharma, INC. | $37.73 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $33.50 | 2019 | |
| Cmp Pharma, INC. | $33.02 | 2022 | |
| Biosense Webster, INC. | $21.15 | 2025 | Carto 3 |
| Cordis US Corp. | $20.69 | 2025 | Mynx Control Venous |
| Heartflow, INC. | $18.11 | 2025 | |
| Medicomp INC | $18.10 | 2019 | |
| Bracco Diagnostics INC. | $17.83 | 2019 | |
| Daiichi Sankyo INC. | $17.08 | 2024 | Injectafer |
| Baxter Healthcare | $15.70 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Medtronic Vascular, INC. | $14.55 | 2020 | |
| Cardinal Health 200 LLC | $13.55 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayar Jundi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.